American Oriental Bioengineering's Marketing Initiatives Enhance Results of Recently Acquired Heilongjiang Songhuajiang Pharmaceutical Limited; New Subsidiary Generates $2.5 Million in New Purchase Orders - Press Releases

American Oriental Bioengineering's Marketing Initiatives Enhance Results of Recently Acquired Heilongjiang Songhuajiang Pharmaceutical Limited; New Subsidiary Generates $2.5 Million in New Purchase Orders
June 27, 2005
BEIJING--(BUSINESS WIRE)--American Oriental Bioengineering, Inc. (OTCBB: AOBO), a rapidly growing Chinese company which produces and distributes a broad range of pharmaceutical and nutraceutical products, announced today that recent marketing initiatives for Heilongjiang Songhuajiang Pharmaceutical Limited (HSPL), its recently acquired subsidiary, have generated $2.5 million in new orders. For more than 50 years, HSPL has played a leading role in the Chinese pharmaceutical industry. Its focus on R&D resulted in proprietary products such as Shuanghuanglian Lyophilized Powder Injection. The product is an antiviral medicine and a most highly regarded herbal products approved by the China FDA for the treatment of SARS.
The Company recently held a series of promotional meetings in eight provinces and municipalities throughout China, including Heilongjiang, Hebei, Henan, Anhui, Xingjaing, Hunan, Guangdong, Guangxi, Beijing, Tianjing. In these meetings, AOBO's technical and sales and marketing staff hosted agencies, distributors and customers to enhance awareness of HSPL's products. Over 4,150 distributors attended.
"Since acquiring HSPL we have taken several significant initiatives to expand its revenue base," said Tony (Shujun) Liu, AOBO's Chief Executive Officer. "As a private company, we have begun several marketing programs to capitalize on the extensive investments that HSPL has made in product development. We have also increased our customer base through expanded distribution channels, as demonstrated by the strong attendance at our recent meetings. We believe that HSPL's unique product line affords AOBO a competitive advantage in the market, and we plan to capitalize on many of its innovative products through further marketing activities in the second half of the year."
About American Oriental Bioengineering, Inc.
American Oriental Bioengineering, Inc. (AOBO) is a leading Chinese biotechnology company that uses proprietary processes for producing soybean protein peptide more efficiently than traditional extracting techniques. These techniques are used to manufacture and formulate supplemental and medicinal products. Soybean peptides are used widely in general food, health food products and medicines, among other applications. AOBO also produces Cease-Enuresis Soft Gel, the only Chinese FDA-approved first grade, prescription medicine that is specially formulated to help alleviate bed-wetting and incontinence. The Company is a leading producer of products in both the nutriceuticals and pharmaceuticals areas in China. For more information, visit http://www.bioaobo.com.